News
-
-
-
PRESS RELEASE
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
NanoViricides, Inc. reports a new research report with 'Outperform' rating and target price of $6.00. Interview with President on antiviral drugs and future plans -
-
-
PRESS RELEASE
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
NanoViricides, Inc. updates advancement of NV-387 broad-spectrum antiviral drug towards Phase II Clinical Trial for Bundibugyo Ebolavirus treatment in the DRC amid expanding outbreak. An oral gummies formulation has potential against Ebola viruses -
-
-
PRESS RELEASE
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
NanoViricides, Inc. receives Rare Pediatric Disease Drug (RPDD) Designation from US FDA for antiviral drug NV-387 for Measles treatment, offering potential Priority Review Voucher benefits. Drug shows promise against rising Measles cases globally -
